Result of AGM

RNS Number : 7019B

Allergy Therapeutics PLC

19 April 2012

 



19 April 2012

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

General Meeting Results

Further to the announcement released by Allergy Therapeutics plc (AIM: AGY) yesterday relating to the results of the Offer, Allergy Therapeutics announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed. The first two resolutions concerned the waiver of Rule 9 of the Takeover Code and were subject to a mandatory poll vote. The third resolution granted the directors authority to allot shares and the fourth resolution disapplied the pre-emption rights of shareholders.

The full text of the resolutions can be found in the Notice of the Meeting in the Circular published by the Company on 30 March 2012 and on the Company's website - www.allergytherapeutics.com.

The votes for Resolutions 1 & 2, decided on a poll at the meeting, were as follows:

	For	%	Against	%	Total votes Cast
Resolution 1 (ordinary resolution) - Waiver of Rule 9 CFR International Spa.	76,549,173	88.56	9,889,283	11.44	86,438,456
Resolution 2 (ordinary resolution) - Waiver of Rule 9 Wild Indigo S.A.	76,549,173	88.56	9,889,283	11.44	86,438,456

For Resolutions 3 & 4, decided on a show of hands, the following proxy votes were received prior to the meeting: 

	For	%	Against	%	Vote Withheld	%	Total votes Cast
Resolution 3 (ordinary resolution) - Authority to allot shares.	54,051,809	66.43	9,889,283	12.16	17,416,364	21.41	81,359,456
Resolution 4 (special resolution) - Dissapplication of pre-emption rights.	54,054,269	66.44	9,889,283	12.16	17,414,864	21.40	81,359,456

Application has been made for the admission to trading on AIM ("Admission") of 96,141,367 ordinary shares of 0.1p each with Admission expected to take place on 20 April 2012.

Following Admission the Company's issued share capital will consist of 406,912,981 ordinary shares of 0.1p each with voting rights attached to each share. The Company has no shares in Treasury, therefore the total number of voting rights in the Company will be 406,912,981.

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FSA's Disclosure and Transparency Rules. 

Capitalised terms used, but not defined in this announcement shall have the meaning as given to them in the announcement and Circular published by the Company on 30 March 2012.

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson / Clare Terlouw
FTI Consulting	[phone]
Jonathan Birt / Susan Quigley

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

RAGSFEFLUFESESL